Bronchogen

Bronchogen is a synthetic four-amino-acid peptide from the bioregulator programme run by Vladimir Khavinson's group in St. Petersburg. Among the organ-branded peptides in that family it is unusual in one respect: somebody actually built a disease model for it, giving rats intermittent nitrogen dioxide for 60 days to produce COPD-like airway damage.

There is no receptor. The proposed mechanism is direct interaction with DNA: microcalorimetry found the peptide raised the melting temperature of calf thymus and mouse liver DNA by 3.1°C, binding non-selectively between AT and GC base pairs, and labelled peptide was seen reaching the nucleolus of HeLa cells. Neither result explains why a DNA-binding tetrapeptide would act on airway lining rather than on every tissue it reaches.

No regulator has approved it for anything. The rat work reported reversal of goblet-cell hyperplasia, restored ciliated epithelium, less neutrophilic infiltration and higher secretory IgA and surfactant protein B ( Kuzubova et al., Bull Exp Biol Med 2015; Titova et al., Ross Fiziol Zh 2017, in Russian). Those are rodent histology endpoints, not a claim about asthma or COPD in people.

Absence reflects obscurity, not review; S0 still covers substances lacking approval for human therapeutic use. Tested athletes should ask their national anti-doping organisation.

No toxicology study, dose-ranging study or adverse-event series is indexed in PubMed. The rat experiments were efficacy experiments; they were not designed to detect harm and did not report on it. The record is silent in either direction, before the separate question of whether a vial bought online contains the labelled peptide.

Human absorption, distribution, half-life and clearance figures do not exist in the peer-reviewed literature, so no dose-response discussion is possible and none is offered here.

Sold as a lyophilised powder, shelved with Cardiogen and Cartalax — a marketing convention, not evidence that those compounds differ from one another.

A PubMed search returns roughly a dozen records, several of them Hungarian-language surgical reports on bronchogenic cysts that merely match the search string. The genuine hits sit in Bulletin of Experimental Biology and Medicine and Advances in Gerontology, with Khavinson or his collaborators on most author lists: internally consistent, externally unreplicated.

For deeper dives on this peptide, see:

• Bronchogen benefits and areas of interest
• Bronchogen side effects and safety context
• Bronchogen dosing concepts (educational)
• Bronchogen research and evidence overview

Is there any human evidence for Bronchogen? No. Every published experiment naming it used rats, isolated DNA or cultured cells; no clinical trial has been registered or published.

What is a "peptide bioregulator"? A term coined inside the St. Petersburg school for two-to-four-residue peptides claimed to bind DNA and switch tissue-specific genes on. It is one group's hypothesis, not a recognised pharmacological class.

How does it differ from Cartalax or Testagen? By one amino acid and by the organ printed on the label. Bronchogen is the one with an actual lung model behind it; Cartalax has never been tested in cartilage, and Testagen has essentially no biological study at all.

Is it approved anywhere? Not by the FDA, EMA, MHRA or any comparable authority.